NuCana plc (NCNA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NCNA SEC filings page.
This page shows NuCana plc (NCNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
NuCana plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
NuCana plc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
NuCana plc reported a net loss of $39.5M while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
NuCana plc reported an operating loss of $27.0M against $17.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
NuCana plc's EBITDA was -$26.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
NuCana plc reported a net loss of $39.5M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
NuCana plc recorded an outflow of $10.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
NuCana plc held $32.6M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
NuCana plc's ROE was -120.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 198.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
NuCana plc invested $17.1M in research and development in fiscal year 2025. This represents a decrease of 24.1% from the prior year.
NuCana plc reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
NCNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $17.1M-24.1% | $22.6M-29.4% | $31.9M-27.4% | $44.0M-11.5% | $49.7M+40.5% | $35.4M+35.2% | $26.2M+21.8% | $21.5M-10.1% | $23.9M+145.2% | $9.8M+16.9% | $8.3M |
| Operating Income | -$27.0Mn/m | -$28.6Mn/m | -$41.8Mn/m | -$47.2Mn/m | -$64.7Mn/m | -$49.8Mn/m | -$35.4Mn/m | -$24.4Mn/m | -$34.8Mn/m | -$10.4Mn/m | -$10.2M |
| EBITDA | -$26.7Mn/m | -$27.9Mn/m | -$41.0Mn/m | -$46.4Mn/m | -$63.4Mn/m | -$48.5Mn/m | -$34.5Mn/m | -$23.9Mn/m | -$34.5Mn/m | -$10.3Mn/m | -$10.1M |
| Interest Expense | $17.0Mn/m | $0n/m | $0-100.0% | $25K+4.4% | $24K-31.6% | $36K+27.5% | $28K | N/A | $2.4M | N/A | N/A |
| Income Tax | -$1.6Mn/m | -$4.3Mn/m | -$5.6Mn/m | -$7.8Mn/m | -$9.8Mn/m | -$7.5Mn/m | -$5.6Mn/m | -$5.4Mn/m | -$3.2Mn/m | -$2.6Mn/m | -$1.7M |
| Net Income | -$39.5Mn/m | -$23.8Mn/m | -$35.2Mn/m | -$38.7Mn/m | -$54.7Mn/m | -$41.9Mn/m | -$28.4Mn/m | -$17.7Mn/m | -$31.2Mn/m | -$7.5Mn/m | -$7.9M |
| EPS (Basic) | $0.00 | -$0.33 | -$0.68n/m | -$0.74n/m | -$1.05 | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | $0.00 | -$0.33 | -$0.68n/m | -$0.74n/m | -$1.05 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, Diluted Shares (Avg).
NCNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.1M+116.9% | $18.5M-47.8% | $35.4M-49.6% | $70.4M-32.7% | $104.6M-29.0% | $147.3M+57.9% | $93.2M-16.2% | $111.3M-14.6% | $130.4M+288.3% | $33.6M | N/A |
| Current Assets | $36.1M+135.2% | $15.4M-51.8% | $31.9M-51.9% | $66.3M-31.4% | $96.7M-30.5% | $139.1M+60.9% | $86.5M-19.0% | $106.7M-16.1% | $127.1M+299.2% | $31.9M | N/A |
| Cash & Equivalents | $32.6M+285.9% | $8.5M-61.5% | $21.9M-56.6% | $50.6M-37.8% | $81.4M-31.8% | $119.3M+73.1% | $68.9M-29.8% | $98.2M-16.2% | $117.3M+375.6% | $24.7M+18.5% | $20.8M |
| Accounts Receivable | $1.1M-1.1% | $1.2M-66.1% | $3.4M-28.8% | $4.8M-14.9% | $5.6M-11.2% | $6.3M+1.2% | $6.2M+108.0% | $3.0M-27.2% | $4.1M | N/A | N/A |
| Total Liabilities | $7.4M-32.9% | $11.0M-32.9% | $16.5M-31.0% | $23.9M+48.2% | $16.1M+37.6% | $11.7M+30.7% | $9.0M+25.4% | $7.1M+79.7% | $4.0M+63.1% | $2.4M | N/A |
| Current Liabilities | $6.4M-40.6% | $10.9M-32.8% | $16.2M-30.7% | $23.3M+47.4% | $15.8M+42.1% | $11.1M+35.7% | $8.2M+15.5% | $7.1M+80.0% | $3.9M+62.1% | $2.4M | N/A |
| Non-Current Liabilities | $960K+397.9% | $193K-39.0% | $316K-40.8% | $534K+88.3% | $284K-49.8% | $564K-24.6% | $748K+2155.2% | $33K+36.3% | $24Kn/m | $0 | N/A |
| Total Equity | $32.7M+338.8% | $7.5M-60.7% | $19.0M-59.2% | $46.5M-47.5% | $88.5M-34.7% | $135.6M+60.8% | $84.3M-19.1% | $104.1M-17.6% | $126.4M+305.9% | $31.1M-29.5% | $44.2M |
| Retained Earnings | -$339.3Mn/m | -$280.8Mn/m | -$264.7Mn/m | -$218.1Mn/m | -$202.1Mn/m | -$151.1Mn/m | -$106.2Mn/m | -$75.1Mn/m | -$61.1Mn/m | -$27.5M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
NCNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.0Mn/m | -$23.9Mn/m | -$33.7Mn/m | -$28.0Mn/m | -$32.2Mn/m | -$29.5Mn/m | -$31.6Mn/m | -$15.6Mn/m | -$11.8Mn/m | -$11.4Mn/m | -$6.6M |
| Depreciation & Amortization | $368K-43.6% | $654K-10.8% | $733K-17.1% | $884K-30.5% | $1.3M+4.6% | $1.2M+27.6% | $953K+101.2% | $474K+80.4% | $262K+110.6% | $125K+92.0% | $65K |
| Capital Expenditures | $0-100.0% | $5K-1.7% | $5K-64.8% | $14K-83.2% | $86K-82.5% | $493K+708.0% | $61K-77.2% | $268K-46.5% | $501K+2605.0% | $19K+109.2% | $9K |
| Free Cash Flow | -$10.0Mn/m | -$23.9Mn/m | -$33.7Mn/m | -$28.0Mn/m | -$32.2Mn/m | -$30.0Mn/m | -$31.7Mn/m | -$15.9Mn/m | -$12.3Mn/m | -$11.4Mn/m | -$6.6M |
| Investing Cash Flow | $214K+116.2% | $99K-97.3% | $3.7M+2439.4% | $145Kn/m | -$4.8Mn/m | -$1.8Mn/m | -$192Kn/m | -$831Kn/m | -$1.3M-106.9% | $18.4Mn/m | -$267K |
| Financing Cash Flow | $33.6M+228.1% | $10.2Mn/m | -$68Kn/m | -$194Kn/m | -$132K-100.2% | $84.4Mn/m | -$62K-123.6% | $264K-99.7% | $105.2M+42529.5% | $247K | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
NCNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -120.7%+198.4pp | -319.1%-133.4pp | -185.6%-102.4pp | -83.2%-21.3pp | -61.8%-30.9pp | -30.9%+2.8pp | -33.7%-16.8pp | -17.0%+7.7pp | -24.7%-0.7pp | -24.0%-6.2pp | -17.8% |
| Return on Assets | -98.4%+30.2pp | -128.6%-29.2pp | -99.4%-44.4pp | -55.0%-2.6pp | -52.3%-23.9pp | -28.5%+2.0pp | -30.5%-14.6pp | -15.9%+8.1pp | -24.0%-1.7pp | -22.2% | N/A |
| Current Ratio | 5.60+4.2x | 1.42-0.6x | 1.97-0.9x | 2.84-3.3x | 6.11-6.4x | 12.49+2.0x | 10.54-4.5x | 15.02-17.2x | 32.22+19.1x | 13.09 | N/A |
| Liabilities-to-Equity | 0.23-1.3x | 1.48+0.6x | 0.87+0.4x | 0.51+0.3x | 0.18+0.1x | 0.090.0x | 0.110.0x | 0.070.0x | 0.030.0x | 0.08 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NuCana plc NCNA | FY2025 | N/A | -$39.5M | N/A | $4.0M | — |
| PharmaCyte Biotech, Inc. PMCB | FY2026 | $0 | -$19.4M | N/A | $3.7M | — |
| Alzamend Neuro, Inc. ALZN | FY2026 | N/A | -$8.8M | N/A | $6.0M | — |
| AIM ImmunoTech Inc. AIM | FY2025 | $88K | -$14.0M | N/A | $6.6M | — |
| Acurx Pharmaceuticals, Inc. ACXP | FY2025 | N/A | -$8.0M | N/A | $4.9M | — |
Where NuCana plc Ranks
Frequently Asked Questions
Is NuCana plc profitable?
No, NuCana plc (NCNA) reported a net loss of $39.5M in fiscal year 2025.
What is NuCana plc's EBITDA?
NuCana plc (NCNA) had EBITDA of -$26.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NuCana plc's return on equity (ROE)?
NuCana plc (NCNA) has a return on equity of -120.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NuCana plc's free cash flow?
NuCana plc (NCNA) recorded an outflow of $10.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NuCana plc's operating cash flow?
NuCana plc (NCNA) recorded an outflow of $10.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NuCana plc's total assets?
NuCana plc (NCNA) had $40.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NuCana plc's capital expenditures?
NuCana plc (NCNA) reported no capital expenditure during fiscal year 2025.
How much does NuCana plc spend on research and development?
NuCana plc (NCNA) invested $17.1M in research and development during fiscal year 2025.
What is NuCana plc's current ratio?
NuCana plc (NCNA) had a current ratio of 5.60 as of fiscal year 2025, which is generally considered healthy.
What is NuCana plc's liabilities-to-equity ratio?
NuCana plc (NCNA) had a liabilities-to-equity ratio of 0.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is NuCana plc's return on assets (ROA)?
NuCana plc (NCNA) had a return on assets of -98.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NuCana plc's P/E ratio?
NuCana plc (NCNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.0M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NuCana plc's price-to-sales ratio?
NuCana plc (NCNA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.0M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NuCana plc's Piotroski F-Score?
NuCana plc (NCNA) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NuCana plc's earnings high quality?
NuCana plc (NCNA) reported a net loss of $39.5M while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NuCana plc cover its interest payments?
NuCana plc (NCNA) reported an operating loss of $27.0M against $17.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.